GBI Research, April 2011, Pages: 105
BiotechM&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Summary
GBI Research's pharmaceutical research, “BiotechM
MarketLine, Sep 2011, Pages: 26
undertaken by an organization to sustain its competitive advantage.
Project Description:
Datamonitors' Nuron Biotech Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes
Decision Resources, Inc., June 2010, Pages: 33
in biotech companies in 2009. What types of biotech companies are attracting VC investments? Which technologies are attracting the biggest VC investments?
- Although merger and acquisition (M&A) activity
Decision Resources, Inc., May 2011
companies are attracting VC investment? Which technologies are attracting the most VC investment?
- Although no megamergers occurred in 2010, merger and acquisition (M&A) activity for biotechs in 2010
Decision Resources, Inc., June 2007, Pages: 27
; and target identification and validation.
- Mergers and acquisitions: a review of high-value ($100 million+) M&A deals involving biotech, including a look at reverse mergers.
- Deal participants
MarketLine, Dec 2011, Pages: 43
business segments
- Intelligence on Marina Biotech, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
Decision Resources, Inc., May 2009, Pages: 37
a litmus test of the strategic objectives of pharmaceutical companies. M&As also have become an important instrument for biotech companies that are seeking to survive or become stronger. What are the current
Datamonitor, June 2011, Pages: 42
Biotech, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- Captures the latest news about Marina
Business Insights, June 2009, Pages: 104
IPO was the floatation of nanotechnology diagnostics company Nanosphere, which raised US$112.7 million in October 2007.
Several recent biotechM&A deals have resulted from partnerships established
Business Insights, Sep 2008, Pages: 143
to market has risen from about $100m in 1990 to nearly $1b in 2008. For biotechs, alliances provide much-needed funding without which many companies would be unable to continue their R&D activities.
“The trend
Takeda Pacific, June 2007, Pages: 130
This report focuses on the market for biomarkers and tests used in pharma/ biotech drug R&D. The study reviews the market by looking at key alliances, pharma/ biotech research and development
GlobalData, Sep 2011, Pages: 46
: Marina Biotech's CRN Technology Found To Be Highly Active As microRNA Antagonist
May 16, 2011: Marina Biotech Reports Net Loss Of $3.7m For Q1 2011
Apr 26, 2011: Marina Biotech Publishes Preclinical
Global Industry Analysts, Inc., April 2011, Pages: 402
and niche players such as Advanced Enzymes Technologies Ltd., Ajeet Seeds Ltd., Anthem BioSciences Pvt. Ltd., Bharat Biotech International Limited, Bharat Serums and Vaccines Ltd., Biocon Limited, Syngene
Bioplan Associates Inc., Jan 2008, Pages: 766
their roots back several thousand years through schools of healing practice. The Indian government is actively developing that experience into a sound biotech industry. We cover Indian government policies
Venture Planning Group, Sep 2011, Pages: 198
Stago Star 4/8
- Helena Laboratories Cascade 480
- Helena Laboratories Cascade M
- Helena Laboratories PACKS-4
- Helena THOR
- Instrumentation Laboratory ACL 100 and 1000 series
- Instrumentation
GlobalData, Oct 2011, Pages: 15
FIT Biotech Oyj - Product Pipeline Analysis
Summary
FIT Biotech Oyj Plc. (FIT Biotech) is a biotechnology company principally engaged in the development and distribution of therapeutic products
